Fig. 3

Suppression of ERRα enhances the antitumour property of trametinib in colon cancer cells. a Cell proliferation was measured using the Cell Counting Kit-8 (CCK-8) assay in the HCT116 and SW480 cells treated with trametinib at 25 nm, 50 nM and 100 nM for 3 d. b WB for ERRα, IDH3A, c-Myc and Cyclin D1 in the HCT116 and SW480 cells treated with the indicated concentrations of trametinib (0–100 nM) or DMSO for 48 h. c CCK-8 assay for the HCT116 and SW480 cells treated with DMSO or trametinib (10 nM) (or/and 20 ng/μl EGF) for 3 d. d, e Clonogenic assays and qualitative analysis of the HCT116 and SW480 cells cultured with DMSO or 10 nM trametinib (or/and 20 ng/μl EGF) at day 7 (* P< 0.05; ** P< 0.01; *** P< 0.001). The data are presented as the mean±SD of the experiments performed in triplicate. f WB for ERRα, c-Myc and Cyclin D1 in the HCT116 and SW480 cells treated with the DMSO or 10 nM trametinib for 48 h (or/and 20 ng/μl EGF) for 2 d. g CCK-8 assay for the HCT116 and SW480 cells treated with shERRα#2 (or/and 50 nM trametinib) for 3 d. h, i Clonogenic assays and qualitative analysis of the HCT116 and SW480 cells cultured with DMSO or 50 nM trametinib (or/and shERRα#2) at day 7. j WB for ERRα, IDH3A, c-Myc and Cyclin D1 in the HCT116 and SW480 cells treated with shERRα#2 (or/and 50 nM trametinib) for 2 d. k Dual luciferase reporter gene assay of the SW480 cells treated with shNC or shERRα#2 (or/and 50 nM trametinib) for 48 h. l CCK-8 assay for the HCT116 and SW480 cells treated with 50 nM trametinib and 5 μM XCT790 for 3 d. m, n Clonogenic assays and qualitative analysis of the HCT116 and SW480 cells cultured with DMSO or 50 nM trametinib (or/and 5 μM XCT790) at day 7. o WB for ERRα, IDH3A, c-Myc and Cyclin D1 in the HCT116 and SW480 cells cultured with DMSO or 50 nM trametinib (or/and 5 μM XCT790) for 48 h